R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
27 Setembro 2022 - 3:00AM
Business Wire
Meeting to highlight Company’s innovative portfolio, supported
by updated clinical data, demonstrating the potential of
therapeutic vaccine and oncolytic virus candidates to improve
cancer patient outcomes
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech
company that designs and develops virus-based immunotherapeutics
against cancer, will host today an R&D event for investors and
research analysts in Paris.
Hedi Ben Brahim, CEO of Transgene, commenting on the
Company’s R&D Day said: “Today’s event will highlight our world
leading scientific and translational expertise which has allowed us
to design the next generation of virus-based immunotherapies
against cancer. We will provide updated data on the previous Phase
Ib/II trial of TG4001 and avelumab in HPV16-positive cancer
patients and the updated clinical follow up of patients enrolled in
the two Phase I trials with TG4050, which are all positive and
consistent with previous findings. In addition, we will outline the
progress we have made with our exciting Invir.IO™ platform, which
via intravenous administration could significantly broaden the
potential of oncolytic viral therapies. I would like to thank our
expert speakers for participating in our R&D event which I am
confident will demonstrate that Transgene remains on track to
deliver a number of important value adding clinical milestones over
the next 18 months.”
The event, which features presentations by leading clinicians
and scientists from around the world, as well as key members of the
Transgene management team, provides insights on:
- TG4001, with updated data from the previous trial
(Phase Ib/II) evaluating the combination of TG4001 and avelumab in
HPV16-positive cancers; - TG4050, with updated follow up
data from the two Phase I trials in ovarian cancer and head and
neck cancer; - The progress of the Invir.IO™ platform, with
a focus on a novel oncolytic virus vectorizing human IL-12 that has
been designed to be administered intravenously.
The R&D Day’s key speakers, which also includes key
members of Transgene’s management team, are:
- Jean-Pierre Delord, MD, PhD, General Manager of IUCT Oncopole
of Toulouse, will present: “TG4001 - a HPV16 Therapeutic vaccine in
Phase II”.
- Christian Ottensmeier, MD, PhD, FRCP, Professor of
Immuno-oncology at the University of Liverpool, The Clatterbridge
Cancer Center NHS Foundation Trust, will present: “From the design
of the myvac® platform to first immunological and clinical
readouts, Update on the head and neck trial of TG4050”.
- Matthew Block, MD, PhD, Medical oncologist at the Mayo Clinic,
will present: “TG4050, a personalized therapeutic vaccine in the
treatment of ovarian cancer”.
- Adel Samson, MD, PhD, Clinical Associate Professor, CRUK
Clinician Scientist and Honorary Medical Oncologist from the
University of Leeds, will present: “Assessing novel routes of
administration (IV or locoregional route) with TG6002”.
- Pedro Romero, MD, Chief Editor of the JITC and Deputy
scientific managing director of the Lausanne Branch of the Ludwig
Institute for Cancer Research, will present: “Opportunities in the
immuno-oncology field”.
The full agenda of the Transgene R&D Day can be accessed on
Transgene’s website, www.transgene.fr, in the Investor Events and
presentation section.
The live webcast will also be accessible via the following link:
R&D Day live
presentation.
***
About Transgene Transgene (Euronext: TNG) is a
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of two therapeutic vaccines (TG4001 for the
treatment of HPV-positive cancers, and TG4050, the first
individualized therapeutic vaccine based on the myvac® platform) as
well as two oncolytic viruses (TG6002 for the treatment of solid
tumors, and BT-001, the first oncolytic virus based on the
Invir.IO™ platform). With Transgene’s myvac® platform, therapeutic
vaccination enters the field of precision medicine with a novel
immunotherapy that is fully tailored to each individual. The myvac®
approach allows the generation of a virus-based immunotherapy that
encodes patient-specific mutations identified and selected by
Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on
its viral vector engineering expertise to design a new generation
of multifunctional oncolytic viruses. Transgene has an ongoing
Invir.IO™ collaboration with AstraZeneca. Additional information
about Transgene is available at: www.transgene.fr. Follow us on
Twitter: @TransgeneSA
Transgene disclaimer This press release contains
forward-looking statements, which are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. The occurrence of any of these
risks could have a significant negative outcome for the Company’s
activities, perspectives, financial situation, results, regulatory
authorities’ agreement with development phases, and development.
The Company’s ability to commercialize its products depends on but
is not limited to the following factors: positive pre-clinical data
may not be predictive of human clinical results, the success of
clinical studies, the ability to obtain financing and/or
partnerships for product manufacturing, development and
commercialization, and marketing approval by government regulatory
authorities. For a discussion of risks and uncertainties which
could cause the Company’s actual results, financial condition,
performance or achievements to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
(“Facteurs de Risque”) section of the Universal Registration
Document, available on the AMF website (http://www.amf-france.org)
or on Transgene’s website (www.transgene.fr). Forward-looking
statements speak only as of the date on which they are made, and
Transgene undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the
future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220926005562/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media Transgene: MEDiSTRAVA Consulting David
Dible/Sylvie Berrebi +44 (0)203 928 6900
transgene@medistrava.com
Transgene (EU:TNG)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Transgene (EU:TNG)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024